RT Journal Article
SR Electronic
T1 Globally altered epigenetic landscape and lagging osteogenic differentiation in H3.3-G34W-mutant giant cell tumor of bone
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.26.20089888
DO 10.1101/2020.05.26.20089888
A1 Lutsik, Pavlo
A1 Baude, Annika
A1 Mancarella, Daniela
A1 Öz, Simin
A1 Kühn, Alexander
A1 Toth, Reka
A1 Hey, Joschka
A1 Toprak, Umut H.
A1 Lim, Jinyeong
A1 Nguyen, Viet Ha
A1 Jiang, Chao
A1 Mayakonda, Anand
A1 Hartmann, Mark
A1 Rosemann, Felix
A1 Breuer, Kersten
A1 Vonficht, Dominik
A1 Grünschläger, Florian
A1 Lee, Suman
A1 Schuhmacher, Maren Kirstin
A1 Kusevic, Denis
A1 Jauch, Anna
A1 Weichenhan, Dieter
A1 Zustin, Jozef
A1 Schlesner, Matthias
A1 Haas, Simon
A1 Park, Joo Hyun
A1 Park, Yoon Jung
A1 Oppermann, Udo
A1 Jeltsch, Albert
A1 Haller, Florian
A1 Fellenberg, Jörg
A1 Lindroth, Anders M.
A1 Plass, Christoph
YR 2020
UL http://medrxiv.org/content/early/2020/05/27/2020.05.26.20089888.abstract
AB The neoplastic stromal cells of giant cell tumor of bone (GCTB) carry a mutation in H3F3A, leading to a mutant histone variant, H3.3-G34W, as a sole recurrent genetic alteration. We show that in patient-derived stromal cells H3.3-G34W is incorporated into the chromatin and associates with massive epigenetic alterations on the DNA methylation, chromatin accessibility and histone modification level that can be partially recapitulated in an orthogonal cell line system by the introduction of H3.3-G34W. These epigenetic alterations affect mainly heterochromatic and bivalent regions and provide possible explanations for the genomic instability as well as the osteolytic phenotype of GCTB. The mutation occurs in differentiating mesenchymal stem cells and associates with an impaired osteogenic differentiation. We propose that the observed epigenetic alterations reflect distinct differentiation stages of H3.3 WT and H3.3 MUT stromal cells and add to H3.3-G34W associated changes.Important abbreviations H3.3-G34W, mutated histone variant; H3.3 MUT, stromal cells expressing H3.3-G34W; H3.3 WT, stromal cells expressing wildtype H3.3Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was in part supported by Funds from the Helmholtz Foundation (C.P.), the Korean National Cancer Center (Grant No. 1810050-1 to A.M.L.), the Korean National Research Fund (Grant No. 2017R1E1A1A01073670 to A.M.L.), Oxford NIHR BRC (U.O.), Arthritis Research UK (program grant 20522 to U.O.). P.L., A.B. are DKFZ Postdoctoral Fellows. P.L. was supported by the Hemlholtz Association AMPro Project (ZT00026). A.K., A.M.T., D.M. are fellows of the Helmholtz International Graduate School for Cancer Research, J.H. is fellow of the German-Israeli Helmholtz Graduate School, C.J. is a recipient of a PhD fellowship from the Royal Commission for the Exhibition 1851, China-Oxford Scholarship Fund and UCB.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics comittee HeidedelbergAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll raw sequencing data from WGS, WGBS, ATAC-seq, ChIP-seq, RNA-seq and deep targeted resequencing were obtained from patient samples (therefore restricted) and are being uploaded to European Genome-Phenome Archive (EGA): EGA: EGAS00001003730. Processed sequencing data and microarray data are being uploaded to the ArrayExpress database (E-MTAB-7184). All presented results were obtained with the use of published and publicly available software tools introduced in the Methods section.